DIFFERENTIATED THYROID CANCER, SECONDARY
NCT02702388.Evaluation of the impact of lenvatinib treatment on health‐related quality‐of‐life was a secondary objective of the phase 2 double‐blinded Study 211. This study compared a starting dose of lenvatinib 18 mg/day with the approved starting dose of 24 mg/day in patients with radioiodine‐refractory differentiated thyroid cancer. Health‐related quality‐of‐life of patients in the 18 mg/day arm was not statistically different from that of patients in the 24 mg/day arm. These data, combined with results from the primary analysis (where the lenvatinib starting dose of 18 mg/day did not demonstrate noninferiority to the approved starting dose of lenvatinib 24 mg/day), support the use of the approved lenvatinib starting dose of 24 mg/day in patients with radioiodine‐refractory differentiated thyroid cancer.
